No Data
No Data
Zhuhai Rundu Pharmaceutical: Summary of Half-Year Report in 2024.
Zhuhai Rundu Pharmaceutical: Half-year report for the year 2024.
On July 31st, the number of shareholders holding shares after the market of Zhuhai Rundu Pharmaceutical (002923.SZ) was 14,198.
On August 7th, Gelunhui reported that as of after-market on July 31st, 2024, there were 14,198 shareholder accounts for Zhuhai Rundu Pharmaceutical on the investor interaction platform.
Zhuhai Rundu Pharmaceutical (002923.SZ): Received notification of approval for the marketing application of the active pharmaceutical ingredient, irbesartan potassium, as a chemical raw material.
On August 5th, Gelonhui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) recently received the approval and issuance of the Chemically Synthesized Active Pharmaceutical Ingredient (API) Application Approval Notice for Amiloride Hydrochloride and Valsartan Potassium. The product is an important layout in the company's industry chain in the valsartan field, and it is used to treat primary hypertension.
Zhuhai Rundu Pharmaceutical (002923.SZ): As of after-hours trading on July 19, the number of shareholding households was 14,116.
On July 26, Gelunhui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) stated on the investor interaction platform that the number of shareholders holding shares after the closing on July 19, 2024 was 14,116.
Zhuhai Rundu Pharmaceutical (002923.SZ): CEP certificate obtained for the active pharmaceutical ingredient of voriconazole.
On July 8th, Gelunhui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) recently received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP certificate) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for voriconazole active pharmaceutical ingredient. This drug is a broad-spectrum triazole antifungal drug developed by Pfizer in the United States, and its mechanism of action is to inhibit the cytochrome P450-mediated pathway in fungi.
No Data